EP4228643A4 - Zusammensetzung und verfahren zur prävention und behandlung von covid-19 und atemwegserkrankungen - Google Patents

Zusammensetzung und verfahren zur prävention und behandlung von covid-19 und atemwegserkrankungen

Info

Publication number
EP4228643A4
EP4228643A4 EP21880683.4A EP21880683A EP4228643A4 EP 4228643 A4 EP4228643 A4 EP 4228643A4 EP 21880683 A EP21880683 A EP 21880683A EP 4228643 A4 EP4228643 A4 EP 4228643A4
Authority
EP
European Patent Office
Prior art keywords
covid
prevention
treatment
composition
respiratory diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21880683.4A
Other languages
English (en)
French (fr)
Other versions
EP4228643A1 (de
Inventor
Chee Seong Seet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National University Hospital Singapore Pte Ltd
Original Assignee
National University Hospital Singapore Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University Hospital Singapore Pte Ltd filed Critical National University Hospital Singapore Pte Ltd
Publication of EP4228643A1 publication Critical patent/EP4228643A1/de
Publication of EP4228643A4 publication Critical patent/EP4228643A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP21880683.4A 2020-10-15 2021-10-14 Zusammensetzung und verfahren zur prävention und behandlung von covid-19 und atemwegserkrankungen Pending EP4228643A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10202010250W 2020-10-15
PCT/SG2021/050621 WO2022081093A1 (en) 2020-10-15 2021-10-14 Composition and methods for the prevention and treatment of covid-19 and respiratory illnesses

Publications (2)

Publication Number Publication Date
EP4228643A1 EP4228643A1 (de) 2023-08-23
EP4228643A4 true EP4228643A4 (de) 2025-10-15

Family

ID=81209491

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21880683.4A Pending EP4228643A4 (de) 2020-10-15 2021-10-14 Zusammensetzung und verfahren zur prävention und behandlung von covid-19 und atemwegserkrankungen

Country Status (2)

Country Link
EP (1) EP4228643A4 (de)
WO (1) WO2022081093A1 (de)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5944012A (en) * 1996-03-25 1999-08-31 Pera; Ivo E. Method for dispensing antioxidant vitamins by inhalation background of the invention
WO2022099182A1 (en) * 2020-11-09 2022-05-12 Rucker Capital Advisors Oral rinse, nasal spray and methods for prevention of covid-19 by lowering viral load of covid-19

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004560A (en) * 1998-11-16 1999-12-21 Hsu; Wu-Ching Nasal spray (drop) for treating fever/cold, and its preparation
JP2002059700A (ja) * 2000-08-22 2002-02-26 Osaka Prefecture 虹色発色加工法
US20020137764A1 (en) * 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US20080138397A1 (en) * 2006-10-24 2008-06-12 Aradigm Corporation Processes for taste-masking of inhaled formulations
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
JP6955784B2 (ja) * 2017-07-04 2021-10-27 フルケム リミテッドＦｌｕｃｈｅｍ Ｌｔｄ 水溶解性が向上されたヨード剤及び塩化ナトリウムを含む固体組成物及びその水溶液を含む目、口腔用、鼻腔用又は吸入用抗ウイルス及び抗菌組成物
EP3892275A1 (de) * 2020-04-08 2021-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Aerosolisierung von hcq oder dessen metaboliten zur behandlung von lungeninfektionen
CN111297838A (zh) * 2020-04-08 2020-06-19 宁波合康生物医药科技有限公司 一种抗病毒药物的吸入喷雾剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5944012A (en) * 1996-03-25 1999-08-31 Pera; Ivo E. Method for dispensing antioxidant vitamins by inhalation background of the invention
WO2022099182A1 (en) * 2020-11-09 2022-05-12 Rucker Capital Advisors Oral rinse, nasal spray and methods for prevention of covid-19 by lowering viral load of covid-19

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HECEL ALEKSANDRA ET AL: "Zinc(II)-The Overlooked �minence Grise of Chloroquine's Fight against COVID-19?", PHARMACEUTICALS, vol. 13, no. 9, 1 September 2020 (2020-09-01), pages 228, XP055826848, DOI: 10.3390/ph13090228 *
S. MAGGINI ET AL: "A Combination of High-Dose Vitamin C plus Zinc for the Common Cold", JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, vol. 40, no. 1, 1 February 2012 (2012-02-01), GB, pages 28 - 42, XP055257949, ISSN: 0300-0605, DOI: 10.1177/147323001204000104 *
See also references of WO2022081093A1 *

Also Published As

Publication number Publication date
WO2022081093A1 (en) 2022-04-21
EP4228643A1 (de) 2023-08-23

Similar Documents

Publication Publication Date Title
EP4121019A4 (de) Zusammensetzungen und verfahren zur behandlung und vorbeugung von nicht-malignen atemwegserkrankungen
EP4165025A4 (de) Zusammensetzungen und verfahren zur behandlung und prävention von neurologischen erkrankungen
EP4415755A4 (de) Ace2-gerichtete zusammensetzungen und verfahren zur behandlung von covid-19
EP4221838A4 (de) Snca-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von snca-assoziierten neurodegenerativen erkrankungen
EP4188390A4 (de) Atxn2-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit atxn2-assoziierten neurodegenerativen erkrankungen
EP3740592A4 (de) Verfahren und zusammensetzungen zur behandlung von gefässerkrankungen
EP4188368A4 (de) Zusammensetzungen und verfahren zur behandlung von erkrankungen und störungen
EP4413137A4 (de) Zusammensetzungen und verfahren zur behandlung von cag-wiederholungserkrankungen
EP4518846A4 (de) Zusammensetzungen und verfahren zur behandlung von epilepsie
EP4433076A4 (de) Zusammensetzungen und verfahren zur behandlung von augenerkrankungen und -verletzungen
EP4437108A4 (de) Zusammensetzungen und verfahren zur behandlung neurodegenerativer erkrankungen
EP4188346A4 (de) Nobiletinzusammensetzungen und verfahren zur behandlung und prävention von covid-19 und verwandten erkrankungen
EP4210755A4 (de) Zusammensetzungen und verfahren zur behandlung von neurologischen erkrankungen
EP4442273A4 (de) Verfahren zur prävention und/oder behandlung thromboembolischer erkrankungen
EP4340835A4 (de) Verfahren und zusammensetzungen zur behandlung von herz-kreislauf-erkrankungen
EP4228696A4 (de) Zusammensetzungen und verfahren zur behandlung von bluterkrankungen
EP4456890A4 (de) Zusammensetzungen und verfahren zur behandlung von lungenerkrankungen
EP4408532A4 (de) Zusammensetzungen und verfahren zur behandlung von pcdh19-bedingten erkrankungen
EP4415737A4 (de) Zusammensetzungen und verfahren zur behandlung von hauterkrankungen
EP4561557A4 (de) Zusammensetzungen und verfahren zur behandlung von stoffwechselerkrankungen
EP4413136A4 (de) Zusammensetzungen und verfahren zur behandlung von prionenkrankheiten
EP4412632A4 (de) Zusammensetzungen und verfahren zur behandlung von stoffwechselerkrankungen
EP4479060A4 (de) 3alpha-oh-5beta-pregnan-20-on-zusammensetzungen und verfahren zur behandlung von erkrankungen des zentralnervensystems
EP4395844A4 (de) Zusammensetzungen und verfahren zur behandlung von knochenverletzungen
EP4395894A4 (de) Verfahren zur prävention und behandlung von synukleinopathien

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230330

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101ALI20241009BHEP

Ipc: A61P 31/14 20060101ALI20241009BHEP

Ipc: A61P 11/00 20060101ALI20241009BHEP

Ipc: A61K 9/72 20060101ALI20241009BHEP

Ipc: A61K 33/30 20060101ALI20241009BHEP

Ipc: A61K 31/375 20060101ALI20241009BHEP

Ipc: A61K 33/18 20060101ALI20241009BHEP

Ipc: A61K 31/4706 20060101AFI20241009BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20250911

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4706 20060101AFI20250905BHEP

Ipc: A61K 33/18 20060101ALI20250905BHEP

Ipc: A61K 31/375 20060101ALI20250905BHEP

Ipc: A61K 33/30 20060101ALI20250905BHEP

Ipc: A61K 9/72 20060101ALI20250905BHEP

Ipc: A61P 11/00 20060101ALI20250905BHEP

Ipc: A61P 31/14 20060101ALI20250905BHEP

Ipc: A61K 9/00 20060101ALI20250905BHEP